nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Blacked-out (not amnesia)—Irinotecan—colon cancer	0.0291	0.128	CcSEcCtD
Lithium—IMPA1—renal system—colon cancer	0.0156	0.0644	CbGeAlD
Lithium—GSK3B—embryo—colon cancer	0.0152	0.0626	CbGeAlD
Lithium—IMPA1—lymphoid tissue—colon cancer	0.0129	0.0535	CbGeAlD
Lithium—GSK3B—epithelium—colon cancer	0.0124	0.0511	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—colon cancer	0.0119	0.0493	CbGeAlD
Lithium—IMPA2—renal system—colon cancer	0.0117	0.0483	CbGeAlD
Lithium—GSK3B—renal system—colon cancer	0.0115	0.0474	CbGeAlD
Lithium—Optic atrophy—Vincristine—colon cancer	0.0112	0.0495	CcSEcCtD
Lithium—GSK3A—smooth muscle tissue—colon cancer	0.0104	0.0428	CbGeAlD
Lithium—GSK3A—renal system—colon cancer	0.00998	0.0412	CbGeAlD
Lithium—IMPA2—digestive system—colon cancer	0.00959	0.0396	CbGeAlD
Lithium—GSK3B—lymphoid tissue—colon cancer	0.00953	0.0394	CbGeAlD
Lithium—IMPA1—liver—colon cancer	0.00952	0.0394	CbGeAlD
Lithium—GSK3B—digestive system—colon cancer	0.00941	0.0389	CbGeAlD
Lithium—IMPA2—bone marrow—colon cancer	0.00884	0.0365	CbGeAlD
Lithium—IMPA2—vagina—colon cancer	0.00847	0.035	CbGeAlD
Lithium—GSK3B—vagina—colon cancer	0.00831	0.0343	CbGeAlD
Lithium—GSK3A—digestive system—colon cancer	0.00818	0.0338	CbGeAlD
Lithium—GRIA3—liver—colon cancer	0.0081	0.0335	CbGeAlD
Lithium—GSK3A—bone marrow—colon cancer	0.00754	0.0312	CbGeAlD
Lithium—Toxicity to various agents—Irinotecan—colon cancer	0.00733	0.0323	CcSEcCtD
Lithium—GSK3A—vagina—colon cancer	0.00723	0.0299	CbGeAlD
Lithium—IMPA2—liver—colon cancer	0.00715	0.0295	CbGeAlD
Lithium—Electrocardiogram change—Fluorouracil—colon cancer	0.00702	0.0309	CcSEcCtD
Lithium—GSK3B—liver—colon cancer	0.00701	0.029	CbGeAlD
Lithium—GSK3A—liver—colon cancer	0.0061	0.0252	CbGeAlD
Lithium—IMPA2—lymph node—colon cancer	0.00548	0.0226	CbGeAlD
Lithium—GSK3B—lymph node—colon cancer	0.00538	0.0222	CbGeAlD
Lithium—GSK3A—lymph node—colon cancer	0.00467	0.0193	CbGeAlD
Lithium—Slurred speech—Fluorouracil—colon cancer	0.00449	0.0198	CcSEcCtD
Lithium—Blindness—Vincristine—colon cancer	0.00388	0.0171	CcSEcCtD
Lithium—Taste metallic—Methotrexate—colon cancer	0.00328	0.0145	CcSEcCtD
Lithium—Nystagmus—Vincristine—colon cancer	0.00301	0.0133	CcSEcCtD
Lithium—Chest tightness—Capecitabine—colon cancer	0.00299	0.0132	CcSEcCtD
Lithium—Peripheral coldness—Capecitabine—colon cancer	0.00294	0.013	CcSEcCtD
Lithium—Nystagmus—Fluorouracil—colon cancer	0.00281	0.0124	CcSEcCtD
Lithium—Dysarthria—Irinotecan—colon cancer	0.00221	0.00976	CcSEcCtD
Lithium—Hypothyroidism—Capecitabine—colon cancer	0.00218	0.00963	CcSEcCtD
Lithium—Leukocytosis—Fluorouracil—colon cancer	0.00213	0.00941	CcSEcCtD
Lithium—Dysarthria—Fluorouracil—colon cancer	0.00212	0.00935	CcSEcCtD
Lithium—Salivary hypersecretion—Irinotecan—colon cancer	0.00203	0.00897	CcSEcCtD
Lithium—Hypercalcaemia—Capecitabine—colon cancer	0.00202	0.0089	CcSEcCtD
Lithium—Coma—Vincristine—colon cancer	0.00197	0.00866	CcSEcCtD
Lithium—Urine output increased—Vincristine—colon cancer	0.00194	0.00857	CcSEcCtD
Lithium—Coma—Fluorouracil—colon cancer	0.00183	0.00808	CcSEcCtD
Lithium—Skin ulcer—Capecitabine—colon cancer	0.0018	0.00794	CcSEcCtD
Lithium—Memory impairment—Capecitabine—colon cancer	0.00179	0.00787	CcSEcCtD
Lithium—Polyuria—Vincristine—colon cancer	0.00178	0.00784	CcSEcCtD
Lithium—Psoriasis—Methotrexate—colon cancer	0.00166	0.00732	CcSEcCtD
Lithium—Folliculitis—Methotrexate—colon cancer	0.00166	0.00732	CcSEcCtD
Lithium—Swelling—Fluorouracil—colon cancer	0.00165	0.00728	CcSEcCtD
Lithium—Chest discomfort—Capecitabine—colon cancer	0.00158	0.00698	CcSEcCtD
Lithium—Lethargy—Fluorouracil—colon cancer	0.00149	0.00655	CcSEcCtD
Lithium—Dysarthria—Capecitabine—colon cancer	0.00148	0.00653	CcSEcCtD
Lithium—Ataxia—Vincristine—colon cancer	0.00147	0.00647	CcSEcCtD
Lithium—Dehydration—Vincristine—colon cancer	0.00145	0.0064	CcSEcCtD
Lithium—Coordination abnormal—Capecitabine—colon cancer	0.00143	0.00629	CcSEcCtD
Lithium—Dehydration—Irinotecan—colon cancer	0.00141	0.00623	CcSEcCtD
Lithium—Stupor—Methotrexate—colon cancer	0.0014	0.00616	CcSEcCtD
Lithium—Muscular weakness—Vincristine—colon cancer	0.00138	0.00607	CcSEcCtD
Lithium—Ataxia—Fluorouracil—colon cancer	0.00137	0.00604	CcSEcCtD
Lithium—Depressed level of consciousness—Capecitabine—colon cancer	0.00135	0.00597	CcSEcCtD
Lithium—Urinary incontinence—Capecitabine—colon cancer	0.00135	0.00597	CcSEcCtD
Lithium—Skin ulcer—Methotrexate—colon cancer	0.00134	0.00591	CcSEcCtD
Lithium—Dry skin—Fluorouracil—colon cancer	0.00133	0.00588	CcSEcCtD
Lithium—Muscular weakness—Fluorouracil—colon cancer	0.00128	0.00566	CcSEcCtD
Lithium—Urine output increased—Capecitabine—colon cancer	0.00127	0.00559	CcSEcCtD
Lithium—Erectile dysfunction—Vincristine—colon cancer	0.00124	0.00548	CcSEcCtD
Lithium—Weight decreased—Vincristine—colon cancer	0.00122	0.00538	CcSEcCtD
Lithium—Weight decreased—Irinotecan—colon cancer	0.00119	0.00524	CcSEcCtD
Lithium—Polyuria—Capecitabine—colon cancer	0.00116	0.00511	CcSEcCtD
Lithium—Swelling—Capecitabine—colon cancer	0.00115	0.00509	CcSEcCtD
Lithium—Oliguria—Methotrexate—colon cancer	0.00113	0.00499	CcSEcCtD
Lithium—Dysarthria—Methotrexate—colon cancer	0.0011	0.00486	CcSEcCtD
Lithium—Hallucination—Vincristine—colon cancer	0.00107	0.00474	CcSEcCtD
Lithium—Bradycardia—Irinotecan—colon cancer	0.00107	0.00472	CcSEcCtD
Lithium—Thirst—Capecitabine—colon cancer	0.00107	0.00471	CcSEcCtD
Lithium—Lethargy—Capecitabine—colon cancer	0.00104	0.00458	CcSEcCtD
Lithium—Depressed level of consciousness—Methotrexate—colon cancer	0.00101	0.00444	CcSEcCtD
Lithium—Ataxia—Capecitabine—colon cancer	0.000957	0.00422	CcSEcCtD
Lithium—Alopecia—Vincristine—colon cancer	0.000954	0.00421	CcSEcCtD
Lithium—Coma—Methotrexate—colon cancer	0.000954	0.0042	CcSEcCtD
Lithium—Dehydration—Capecitabine—colon cancer	0.000946	0.00417	CcSEcCtD
Lithium—Urine output increased—Methotrexate—colon cancer	0.000944	0.00416	CcSEcCtD
Lithium—Arrhythmia—Irinotecan—colon cancer	0.00094	0.00414	CcSEcCtD
Lithium—Dry skin—Capecitabine—colon cancer	0.000933	0.00411	CcSEcCtD
Lithium—Alopecia—Irinotecan—colon cancer	0.000929	0.0041	CcSEcCtD
Lithium—Flatulence—Irinotecan—colon cancer	0.000902	0.00398	CcSEcCtD
Lithium—Gastritis—Capecitabine—colon cancer	0.000901	0.00397	CcSEcCtD
Lithium—Arrhythmia—Fluorouracil—colon cancer	0.0009	0.00397	CcSEcCtD
Lithium—Muscular weakness—Capecitabine—colon cancer	0.000898	0.00396	CcSEcCtD
Lithium—Alopecia—Fluorouracil—colon cancer	0.00089	0.00392	CcSEcCtD
Lithium—Agitation—Vincristine—colon cancer	0.000864	0.00381	CcSEcCtD
Lithium—Polyuria—Methotrexate—colon cancer	0.000863	0.0038	CcSEcCtD
Lithium—Vertigo—Vincristine—colon cancer	0.000845	0.00372	CcSEcCtD
Lithium—Vision blurred—Fluorouracil—colon cancer	0.000827	0.00364	CcSEcCtD
Lithium—Vertigo—Irinotecan—colon cancer	0.000823	0.00363	CcSEcCtD
Lithium—Syncope—Irinotecan—colon cancer	0.000821	0.00362	CcSEcCtD
Lithium—Convulsion—Vincristine—colon cancer	0.000815	0.00359	CcSEcCtD
Lithium—Loss of consciousness—Irinotecan—colon cancer	0.000805	0.00355	CcSEcCtD
Lithium—Weight increased—Capecitabine—colon cancer	0.0008	0.00353	CcSEcCtD
Lithium—Weight decreased—Capecitabine—colon cancer	0.000796	0.00351	CcSEcCtD
Lithium—Hyperglycaemia—Capecitabine—colon cancer	0.000793	0.0035	CcSEcCtD
Lithium—Lethargy—Methotrexate—colon cancer	0.000773	0.00341	CcSEcCtD
Lithium—Discomfort—Irinotecan—colon cancer	0.00077	0.0034	CcSEcCtD
Lithium—Oedema—Vincristine—colon cancer	0.000767	0.00338	CcSEcCtD
Lithium—Convulsion—Fluorouracil—colon cancer	0.00076	0.00335	CcSEcCtD
Lithium—Confusional state—Irinotecan—colon cancer	0.000754	0.00332	CcSEcCtD
Lithium—Oedema—Irinotecan—colon cancer	0.000747	0.00329	CcSEcCtD
Lithium—Discomfort—Fluorouracil—colon cancer	0.000738	0.00325	CcSEcCtD
Lithium—Shock—Irinotecan—colon cancer	0.000735	0.00324	CcSEcCtD
Lithium—Anorexia—Vincristine—colon cancer	0.000731	0.00322	CcSEcCtD
Lithium—Confusional state—Fluorouracil—colon cancer	0.000722	0.00318	CcSEcCtD
Lithium—Hypotension—Vincristine—colon cancer	0.000717	0.00316	CcSEcCtD
Lithium—Bradycardia—Capecitabine—colon cancer	0.000717	0.00316	CcSEcCtD
Lithium—Oedema—Fluorouracil—colon cancer	0.000716	0.00316	CcSEcCtD
Lithium—Anorexia—Irinotecan—colon cancer	0.000712	0.00314	CcSEcCtD
Lithium—Ataxia—Methotrexate—colon cancer	0.000712	0.00314	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vincristine—colon cancer	0.000699	0.00308	CcSEcCtD
Lithium—Hypotension—Irinotecan—colon cancer	0.000698	0.00308	CcSEcCtD
Lithium—Anorexia—Fluorouracil—colon cancer	0.000682	0.00301	CcSEcCtD
Lithium—Hypotension—Fluorouracil—colon cancer	0.000669	0.00295	CcSEcCtD
Lithium—Decreased appetite—Vincristine—colon cancer	0.000667	0.00294	CcSEcCtD
Lithium—Somnolence—Irinotecan—colon cancer	0.000664	0.00293	CcSEcCtD
Lithium—Fatigue—Vincristine—colon cancer	0.000662	0.00292	CcSEcCtD
Lithium—Dyspepsia—Irinotecan—colon cancer	0.000658	0.0029	CcSEcCtD
Lithium—Tinnitus—Capecitabine—colon cancer	0.000656	0.00289	CcSEcCtD
Lithium—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000652	0.00287	CcSEcCtD
Lithium—Decreased appetite—Irinotecan—colon cancer	0.00065	0.00286	CcSEcCtD
Lithium—Fatigue—Irinotecan—colon cancer	0.000644	0.00284	CcSEcCtD
Lithium—Somnolence—Fluorouracil—colon cancer	0.000636	0.00281	CcSEcCtD
Lithium—Dyspepsia—Fluorouracil—colon cancer	0.00063	0.00278	CcSEcCtD
Lithium—Arrhythmia—Capecitabine—colon cancer	0.000629	0.00277	CcSEcCtD
Lithium—Gastrointestinal pain—Vincristine—colon cancer	0.000627	0.00277	CcSEcCtD
Lithium—Decreased appetite—Fluorouracil—colon cancer	0.000622	0.00274	CcSEcCtD
Lithium—Alopecia—Capecitabine—colon cancer	0.000622	0.00274	CcSEcCtD
Lithium—Feeling abnormal—Irinotecan—colon cancer	0.000616	0.00271	CcSEcCtD
Lithium—Gastrointestinal pain—Irinotecan—colon cancer	0.000611	0.00269	CcSEcCtD
Lithium—Abdominal pain—Vincristine—colon cancer	0.000607	0.00267	CcSEcCtD
Lithium—Body temperature increased—Vincristine—colon cancer	0.000607	0.00267	CcSEcCtD
Lithium—Flatulence—Capecitabine—colon cancer	0.000604	0.00266	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—colon cancer	0.000603	0.00266	CcSEcCtD
Lithium—Dysgeusia—Capecitabine—colon cancer	0.0006	0.00265	CcSEcCtD
Lithium—Abdominal pain—Irinotecan—colon cancer	0.000591	0.0026	CcSEcCtD
Lithium—Body temperature increased—Irinotecan—colon cancer	0.000591	0.0026	CcSEcCtD
Lithium—Feeling abnormal—Fluorouracil—colon cancer	0.00059	0.0026	CcSEcCtD
Lithium—Drowsiness—Methotrexate—colon cancer	0.000584	0.00257	CcSEcCtD
Lithium—Vision blurred—Capecitabine—colon cancer	0.000578	0.00255	CcSEcCtD
Lithium—Tremor—Capecitabine—colon cancer	0.000574	0.00253	CcSEcCtD
Lithium—Body temperature increased—Fluorouracil—colon cancer	0.000566	0.00249	CcSEcCtD
Lithium—Vertigo—Capecitabine—colon cancer	0.000551	0.00243	CcSEcCtD
Lithium—Asthenia—Vincristine—colon cancer	0.000551	0.00243	CcSEcCtD
Lithium—Syncope—Capecitabine—colon cancer	0.00055	0.00242	CcSEcCtD
Lithium—Loss of consciousness—Capecitabine—colon cancer	0.000539	0.00237	CcSEcCtD
Lithium—Asthenia—Irinotecan—colon cancer	0.000536	0.00236	CcSEcCtD
Lithium—Diarrhoea—Vincristine—colon cancer	0.000525	0.00231	CcSEcCtD
Lithium—Arthralgia—Capecitabine—colon cancer	0.000522	0.0023	CcSEcCtD
Lithium—Discomfort—Capecitabine—colon cancer	0.000515	0.00227	CcSEcCtD
Lithium—Diarrhoea—Irinotecan—colon cancer	0.000511	0.00225	CcSEcCtD
Lithium—Dry mouth—Capecitabine—colon cancer	0.00051	0.00225	CcSEcCtD
Lithium—Dizziness—Vincristine—colon cancer	0.000507	0.00224	CcSEcCtD
Lithium—Confusional state—Capecitabine—colon cancer	0.000504	0.00222	CcSEcCtD
Lithium—Oedema—Capecitabine—colon cancer	0.0005	0.0022	CcSEcCtD
Lithium—Dizziness—Irinotecan—colon cancer	0.000494	0.00218	CcSEcCtD
Lithium—Shock—Capecitabine—colon cancer	0.000492	0.00217	CcSEcCtD
Lithium—Diarrhoea—Fluorouracil—colon cancer	0.00049	0.00216	CcSEcCtD
Lithium—Tinnitus—Methotrexate—colon cancer	0.000489	0.00215	CcSEcCtD
Lithium—Vomiting—Vincristine—colon cancer	0.000488	0.00215	CcSEcCtD
Lithium—Rash—Vincristine—colon cancer	0.000484	0.00213	CcSEcCtD
Lithium—Dermatitis—Vincristine—colon cancer	0.000483	0.00213	CcSEcCtD
Lithium—Headache—Vincristine—colon cancer	0.000481	0.00212	CcSEcCtD
Lithium—Anorexia—Capecitabine—colon cancer	0.000477	0.0021	CcSEcCtD
Lithium—Vomiting—Irinotecan—colon cancer	0.000475	0.00209	CcSEcCtD
Lithium—Dizziness—Fluorouracil—colon cancer	0.000473	0.00209	CcSEcCtD
Lithium—Rash—Irinotecan—colon cancer	0.000471	0.00208	CcSEcCtD
Lithium—Dermatitis—Irinotecan—colon cancer	0.000471	0.00208	CcSEcCtD
Lithium—Headache—Irinotecan—colon cancer	0.000468	0.00206	CcSEcCtD
Lithium—Hypotension—Capecitabine—colon cancer	0.000467	0.00206	CcSEcCtD
Lithium—Alopecia—Methotrexate—colon cancer	0.000463	0.00204	CcSEcCtD
Lithium—Nausea—Vincristine—colon cancer	0.000456	0.00201	CcSEcCtD
Lithium—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000456	0.00201	CcSEcCtD
Lithium—Vomiting—Fluorouracil—colon cancer	0.000455	0.00201	CcSEcCtD
Lithium—Rash—Fluorouracil—colon cancer	0.000451	0.00199	CcSEcCtD
Lithium—Dermatitis—Fluorouracil—colon cancer	0.000451	0.00199	CcSEcCtD
Lithium—Headache—Fluorouracil—colon cancer	0.000448	0.00198	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—colon cancer	0.000447	0.00197	CcSEcCtD
Lithium—Nausea—Irinotecan—colon cancer	0.000444	0.00196	CcSEcCtD
Lithium—Dyspepsia—Capecitabine—colon cancer	0.00044	0.00194	CcSEcCtD
Lithium—Decreased appetite—Capecitabine—colon cancer	0.000435	0.00192	CcSEcCtD
Lithium—Fatigue—Capecitabine—colon cancer	0.000431	0.0019	CcSEcCtD
Lithium—Vision blurred—Methotrexate—colon cancer	0.00043	0.0019	CcSEcCtD
Lithium—Nausea—Fluorouracil—colon cancer	0.000425	0.00187	CcSEcCtD
Lithium—Feeling abnormal—Capecitabine—colon cancer	0.000412	0.00182	CcSEcCtD
Lithium—Vertigo—Methotrexate—colon cancer	0.00041	0.00181	CcSEcCtD
Lithium—Gastrointestinal pain—Capecitabine—colon cancer	0.000409	0.0018	CcSEcCtD
Lithium—Body temperature increased—Capecitabine—colon cancer	0.000395	0.00174	CcSEcCtD
Lithium—Abdominal pain—Capecitabine—colon cancer	0.000395	0.00174	CcSEcCtD
Lithium—Convulsion—Methotrexate—colon cancer	0.000395	0.00174	CcSEcCtD
Lithium—Arthralgia—Methotrexate—colon cancer	0.000388	0.00171	CcSEcCtD
Lithium—Discomfort—Methotrexate—colon cancer	0.000384	0.00169	CcSEcCtD
Lithium—Confusional state—Methotrexate—colon cancer	0.000375	0.00166	CcSEcCtD
Lithium—Asthenia—Capecitabine—colon cancer	0.000359	0.00158	CcSEcCtD
Lithium—Anorexia—Methotrexate—colon cancer	0.000355	0.00156	CcSEcCtD
Lithium—Hypotension—Methotrexate—colon cancer	0.000348	0.00153	CcSEcCtD
Lithium—Diarrhoea—Capecitabine—colon cancer	0.000342	0.00151	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000339	0.0015	CcSEcCtD
Lithium—Somnolence—Methotrexate—colon cancer	0.000331	0.00146	CcSEcCtD
Lithium—Dizziness—Capecitabine—colon cancer	0.000331	0.00146	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—colon cancer	0.000328	0.00144	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—colon cancer	0.000324	0.00143	CcSEcCtD
Lithium—Fatigue—Methotrexate—colon cancer	0.000321	0.00142	CcSEcCtD
Lithium—Vomiting—Capecitabine—colon cancer	0.000318	0.0014	CcSEcCtD
Lithium—Rash—Capecitabine—colon cancer	0.000315	0.00139	CcSEcCtD
Lithium—Dermatitis—Capecitabine—colon cancer	0.000315	0.00139	CcSEcCtD
Lithium—Headache—Capecitabine—colon cancer	0.000313	0.00138	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—colon cancer	0.000307	0.00135	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—colon cancer	0.000304	0.00134	CcSEcCtD
Lithium—Nausea—Capecitabine—colon cancer	0.000297	0.00131	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—colon cancer	0.000294	0.0013	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—colon cancer	0.000294	0.0013	CcSEcCtD
Lithium—Asthenia—Methotrexate—colon cancer	0.000267	0.00118	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—colon cancer	0.000255	0.00112	CcSEcCtD
Lithium—Dizziness—Methotrexate—colon cancer	0.000246	0.00109	CcSEcCtD
Lithium—Vomiting—Methotrexate—colon cancer	0.000237	0.00104	CcSEcCtD
Lithium—Rash—Methotrexate—colon cancer	0.000235	0.00103	CcSEcCtD
Lithium—Dermatitis—Methotrexate—colon cancer	0.000235	0.00103	CcSEcCtD
Lithium—Headache—Methotrexate—colon cancer	0.000233	0.00103	CcSEcCtD
Lithium—Nausea—Methotrexate—colon cancer	0.000221	0.000975	CcSEcCtD
Lithium—GSK3B—B Cell Activation—EGFR—colon cancer	0.00022	0.000414	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—colon cancer	0.00022	0.000414	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—colon cancer	0.00022	0.000413	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—PIK3CA—colon cancer	0.000219	0.000413	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—colon cancer	0.000219	0.000413	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—colon cancer	0.000219	0.000413	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—colon cancer	0.000216	0.000407	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—colon cancer	0.000216	0.000406	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000215	0.000404	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN1A—colon cancer	0.000213	0.000401	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—colon cancer	0.000212	0.0004	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CASP3—colon cancer	0.000212	0.000399	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—AKT1—colon cancer	0.000211	0.000397	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—colon cancer	0.000211	0.000397	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—colon cancer	0.000211	0.000396	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KRAS—colon cancer	0.000208	0.000391	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—colon cancer	0.000207	0.00039	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—colon cancer	0.000207	0.00039	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—PIK3CA—colon cancer	0.000206	0.000389	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—PIK3CA—colon cancer	0.000206	0.000389	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—PIK3CA—colon cancer	0.000206	0.000389	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—colon cancer	0.000206	0.000388	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—colon cancer	0.000206	0.000387	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDH1—colon cancer	0.000205	0.000386	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—colon cancer	0.000205	0.000386	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PIK3CA—colon cancer	0.000205	0.000385	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—colon cancer	0.000204	0.000384	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—colon cancer	0.000203	0.000382	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PIK3CA—colon cancer	0.000203	0.000382	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—colon cancer	0.000203	0.000381	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—colon cancer	0.000202	0.000381	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	0.000202	0.00038	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PIK3CA—colon cancer	0.000202	0.00038	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—colon cancer	0.0002	0.000377	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—CDKN1A—colon cancer	0.0002	0.000376	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—colon cancer	0.000199	0.000375	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—colon cancer	0.000199	0.000375	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—colon cancer	0.000199	0.000374	CbGpPWpGaD
Lithium—IMPA2—Metabolism—EP300—colon cancer	0.000197	0.000371	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BCL2L1—colon cancer	0.000196	0.000368	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—PIK3CA—colon cancer	0.000195	0.000367	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—colon cancer	0.000193	0.000364	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—colon cancer	0.000192	0.000361	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PIK3CA—colon cancer	0.000191	0.00036	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—colon cancer	0.000191	0.000359	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—colon cancer	0.000191	0.000359	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	0.000191	0.000359	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—AKT1—colon cancer	0.00019	0.000358	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PIK3CA—colon cancer	0.00019	0.000358	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—colon cancer	0.000189	0.000356	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—colon cancer	0.000188	0.000354	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PPARG—colon cancer	0.000188	0.000353	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—colon cancer	0.000188	0.000353	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FGFR3—colon cancer	0.000187	0.000352	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—colon cancer	0.000187	0.000352	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—colon cancer	0.000185	0.000348	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—SRC—colon cancer	0.000185	0.000348	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	0.000183	0.000344	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—colon cancer	0.000183	0.000344	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—colon cancer	0.000182	0.000342	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—colon cancer	0.000181	0.000341	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—colon cancer	0.00018	0.00034	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—colon cancer	0.00018	0.000339	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—colon cancer	0.00018	0.000339	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—colon cancer	0.00018	0.000339	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FGFR3—colon cancer	0.00018	0.000338	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—colon cancer	0.000179	0.000337	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—colon cancer	0.000178	0.000335	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—colon cancer	0.000177	0.000333	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—colon cancer	0.000177	0.000332	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—colon cancer	0.000176	0.000331	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—colon cancer	0.000175	0.00033	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—colon cancer	0.000175	0.00033	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	0.000169	0.000318	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—colon cancer	0.000169	0.000317	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—colon cancer	0.000169	0.000317	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	0.000169	0.000317	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—SRC—colon cancer	0.000167	0.000315	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—colon cancer	0.000167	0.000315	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—colon cancer	0.000166	0.000312	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—colon cancer	0.000165	0.00031	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—colon cancer	0.000163	0.000307	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—colon cancer	0.000162	0.000305	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—colon cancer	0.000161	0.000303	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—colon cancer	0.000159	0.0003	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—colon cancer	0.000158	0.000297	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—colon cancer	0.000156	0.000294	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—colon cancer	0.000155	0.000293	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1A—colon cancer	0.000154	0.00029	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2L1—colon cancer	0.000154	0.00029	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—colon cancer	0.000153	0.000288	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—colon cancer	0.000153	0.000287	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—colon cancer	0.000152	0.000286	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	0.000149	0.000281	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1A—colon cancer	0.000148	0.000279	CbGpPWpGaD
Lithium—GSK3A—Immune System—FGFR3—colon cancer	0.000147	0.000277	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—colon cancer	0.000147	0.000276	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—colon cancer	0.000147	0.000276	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—colon cancer	0.000146	0.000274	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—colon cancer	0.000145	0.000273	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—colon cancer	0.000143	0.000269	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SRC—colon cancer	0.000143	0.000269	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—colon cancer	0.000141	0.000265	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—colon cancer	0.000138	0.000261	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—colon cancer	0.000138	0.00026	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—colon cancer	0.000138	0.00026	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—colon cancer	0.000137	0.000258	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SRC—colon cancer	0.000137	0.000258	CbGpPWpGaD
Lithium—GSK3A—Disease—FGFR3—colon cancer	0.000136	0.000256	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—colon cancer	0.000133	0.000251	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—colon cancer	0.000132	0.000249	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—colon cancer	0.000132	0.000248	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—colon cancer	0.00013	0.000245	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—colon cancer	0.00013	0.000244	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—colon cancer	0.000128	0.000242	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—colon cancer	0.000125	0.000235	CbGpPWpGaD
Lithium—GSK3A—Disease—APC—colon cancer	0.000125	0.000235	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—colon cancer	0.000125	0.000234	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—colon cancer	0.000123	0.000231	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—colon cancer	0.00012	0.000226	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SRC—colon cancer	0.000119	0.000225	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—colon cancer	0.000119	0.000224	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—colon cancer	0.000118	0.000222	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—colon cancer	0.000118	0.000222	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—colon cancer	0.000117	0.000221	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—colon cancer	0.000117	0.00022	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—colon cancer	0.000116	0.000219	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—colon cancer	0.000115	0.000216	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—colon cancer	0.000115	0.000216	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—colon cancer	0.000114	0.000214	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—colon cancer	0.000114	0.000214	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—colon cancer	0.000113	0.000214	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—colon cancer	0.000109	0.000206	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGFR3—colon cancer	0.000109	0.000205	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—colon cancer	0.000109	0.000204	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—colon cancer	0.000108	0.000204	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—colon cancer	0.000107	0.000201	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—colon cancer	0.000106	0.0002	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—colon cancer	0.000106	0.000199	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—colon cancer	0.000105	0.000198	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—colon cancer	0.000105	0.000197	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—colon cancer	0.000104	0.000196	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—colon cancer	0.000101	0.000191	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—colon cancer	0.000101	0.000191	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR3—colon cancer	0.000101	0.000189	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—colon cancer	0.0001	0.000189	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—colon cancer	9.88e-05	0.000186	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—colon cancer	9.74e-05	0.000183	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—colon cancer	9.64e-05	0.000181	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR3—colon cancer	9.53e-05	0.000179	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—colon cancer	9.48e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—colon cancer	9.24e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—colon cancer	9.23e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—colon cancer	9.2e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—colon cancer	9.19e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—colon cancer	8.98e-05	0.000169	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—colon cancer	8.87e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—colon cancer	8.86e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—colon cancer	8.75e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—colon cancer	8.73e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—colon cancer	8.68e-05	0.000163	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—colon cancer	8.54e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—colon cancer	8.51e-05	0.00016	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—colon cancer	8.49e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—colon cancer	8.4e-05	0.000158	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—colon cancer	8.38e-05	0.000158	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—colon cancer	8.31e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—colon cancer	8.29e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—colon cancer	8.22e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—colon cancer	8.02e-05	0.000151	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—colon cancer	7.99e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—colon cancer	7.89e-05	0.000149	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—colon cancer	7.7e-05	0.000145	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—colon cancer	7.67e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—colon cancer	7.42e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—colon cancer	7.42e-05	0.00014	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—colon cancer	7.38e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—colon cancer	7.28e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—colon cancer	7.12e-05	0.000134	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR3—colon cancer	7.04e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—colon cancer	7.01e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—colon cancer	6.88e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—colon cancer	6.87e-05	0.000129	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—colon cancer	6.86e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—colon cancer	6.79e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—colon cancer	6.72e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—colon cancer	6.64e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—colon cancer	6.55e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—colon cancer	6.46e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—colon cancer	6.35e-05	0.00012	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—colon cancer	6.32e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—colon cancer	6.31e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—colon cancer	6.29e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—colon cancer	6.27e-05	0.000118	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—colon cancer	6.17e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—colon cancer	6.14e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—colon cancer	6.13e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—colon cancer	6.08e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—colon cancer	6e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—colon cancer	5.94e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—colon cancer	5.91e-05	0.000111	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—colon cancer	5.85e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—colon cancer	5.84e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—colon cancer	5.83e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—colon cancer	5.81e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—colon cancer	5.67e-05	0.000107	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—colon cancer	5.52e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—colon cancer	5.45e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—colon cancer	5.4e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—colon cancer	5.38e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—colon cancer	5.37e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—colon cancer	5.23e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—colon cancer	5.17e-05	9.73e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—colon cancer	5.16e-05	9.72e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—colon cancer	5.08e-05	9.57e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—colon cancer	5.08e-05	9.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—colon cancer	5.07e-05	9.54e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—colon cancer	4.97e-05	9.35e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—colon cancer	4.81e-05	9.06e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—colon cancer	4.8e-05	9.04e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—colon cancer	4.77e-05	8.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—colon cancer	4.71e-05	8.86e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—colon cancer	4.69e-05	8.84e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—colon cancer	4.67e-05	8.79e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—colon cancer	4.56e-05	8.58e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—colon cancer	4.45e-05	8.37e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—colon cancer	4.43e-05	8.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—colon cancer	4.39e-05	8.27e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—colon cancer	4.32e-05	8.13e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—colon cancer	4.31e-05	8.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—colon cancer	4.29e-05	8.08e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—colon cancer	4.09e-05	7.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—colon cancer	4.08e-05	7.68e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—colon cancer	3.99e-05	7.51e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—colon cancer	3.97e-05	7.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—colon cancer	3.95e-05	7.44e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—colon cancer	3.87e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—colon cancer	3.82e-05	7.19e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—colon cancer	3.82e-05	7.18e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—colon cancer	3.78e-05	7.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—colon cancer	3.56e-05	6.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—colon cancer	3.55e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—colon cancer	3.52e-05	6.63e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—colon cancer	3.48e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—colon cancer	3.34e-05	6.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—colon cancer	3.29e-05	6.19e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—colon cancer	3.02e-05	5.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—colon cancer	2.92e-05	5.5e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—colon cancer	2.79e-05	5.26e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—colon cancer	2.47e-05	4.64e-05	CbGpPWpGaD
